Catherine Saï-Maurel

Catherine Saï-Maurel

Auto-generated profile, based on publicly available information

Catherine Saï-Maurel

Centre de Recherche en Cancérologie de Nantes-Angers, Université de Nantes, Inserm, U892, Nantes, France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in EJNMMI Research
Verified
Journal Article
Open access
CRCaroline Rousseau
Caroline Rousseau
ARAnne Lise Ruellan
Anne Lise Ruellan
KBKarine Bernardeau
Karine Bernardeau
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
SGSébastien GOUARD
Sébastien GOUARD
FDFrançois Davodeau
François Davodeau
Background: Overexpression of syndecan-1 (CD138) in breast carcinoma correlates with a poor prognosis and an aggressive phenotype. The objective of this study was to evaluate the potential of targeting CD138 by immuno-PET imaging and radioimmunotherapy (RIT) using the antihuman syndecan-1 B-B4 mAb radiolabeled with either 124I or 131I in nude mice engrafted with the triple-negative MDA-MB-468 breast cancer cell line. Method: The immunoreactivity of 125I-B-B4 (80%) was determined, and the affinity of 125I-B-B4 and the expression of CD138 on MDA-MB-468 was measured in vitro by Scatchard analysis. CD138 expression on established tumors was confirmed by immunohistochemistry. A biodistribution study was performed in mice with subcutaneous MDA-MB-468 and 125I-B-B4 at 4, 24, 48, 72, and 96 h after injection and compared with an isotype-matched control. Tumor uptake of B-B4 was evaluated in vivo by immuno-PET imaging using the 124I-B-B4 mAb. The maximum tolerated dose (MTD) was determined from mice treated with 131I-B-B4 and the RIT efficacy evaluated. Results: 125I-B-B4 affinity was in the nanomolar range (Kd = 4.39 ± 1.10 nM). CD138 expression on MDA-MB-468 cells was quite low (Bmax = 1.19 × 104 ± 9.27 × 102 epitopes/cell) but all expressed CD138 in vivo as determined by immunohistochemistry. The tumor uptake of 125I-B-B4 peaked at 14% injected dose (ID) per gram at 24 h and was higher than that of the isotype-matched control mAb (5% ID per gram at 24 h). Immuno-PET performed with 124I-B-B4 on tumor-bearing mice confirmed the specificity of B-B4 uptake and its retention within the tumor. The MTD was reached at 22.2 MBq. All mice treated with RIT (n = 8) as a single treatment at the MTD experienced a partial (n = 3) or complete (n = 5) response, with three of them remaining tumor-free 95 days after treatment. Conclusion: These results demonstrate that RIT with 131I-B-B4 could be considered for the treatment of metastatic triple-negative breast cancer that cannot benefit from hormone therapy or anti-Her2/neu immunotherapy. Immuno-PET for visualizing CD138-expressing tumors with 124I-B-B4 reinforces the interest of this mAb for diagnosis and quantitative imaging.

1 February 2002
Verified
Journal Article
Closed access
FKFrançoise Kraeber-Bodéré
Françoise Kraeber-Bodéré
CSCatherine Saï-Maurel
Catherine Saï-Maurel
Loic CampionLoic Campion
Loic Campion
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet
EMEric Mirallié
Eric Mirallié
PTPhilippe Thédrez
Philippe Thédrez

17 September 1996 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ADAnne Devys
Anne Devys
PTPhilippe Thedrez
Philippe Thedrez
EGEmmanuel Gautherot
Emmanuel Gautherot
AFAlain Faivre-Chauvet
Alain Faivre-Chauvet
CSCatherine Saï‐Maurel
Catherine Saï‐Maurel
JCJean‐François Chatal
Jean‐François Chatal
In the perspective of radioimmunotherapy (RIT) of micrometastases, we compared, in multicell spheroids (MS), the uptake and retention kinetics of 125I‐F(ab)′2 F6 anti‐carcinoembryonic antigen (CEA) monoclonal antibody (MAb), and the affinity enhancement system (AES) using an anti‐CEA/anti‐DTPA‐indium bispecific antibody (BsMAb) and a 125I‐labeled di‐DTPA‐In‐tyrosine‐lysine bivalent hapten. We used MS of colorectal‐tumor cell lines expressing CEA strongly (LS 174T), weakly (HT‐29) or not at all (HRT‐18). Uptake and retention kinetics of 125I‐F(ab)′2 F6 and 125I‐BsMAb used alone gave similar results. The highest uptake values, obtained with LS 174T MS, were slightly lower with AES than with 125I‐F(ab)′2 F6. However, effective retention half‐lives were longer for AES than for 125I‐F(ab)′2 F6 or for 111In‐labeled monovalent hapten after pre‐incubation of spheroids with BsMAb. Autoradiography showed the same slow and heterogeneous distribution of 125I‐F(ab)′2 F6 and 125I‐BsMAb. These results indicate that the 2‐step technique is more favorable for RIT: uptake values were approximately the same but uptake kinetics were more rapid, and retention half‐life was longer than with the one‐step technique. © 1996 Wiley‐Liss, Inc.